Global Parkinson’s disease treatment market size was valued at USD 4.55 billion in 2021 and is expected to reach USD 7.74 Billion By 2030, growing at a CAGR of 6.2% during the forecast period.
Polaris Market Research recently published a research report on “Parkinson’s Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Levodopa/carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics, and Other Drugs); By Distribution Channel; By Route of Administration; By Patient Care Setting; By Region; Segment Forecast, 2022 – 2030” in its research database.
According to the research report, the global Parkinson’s disease treatment market size was valued at USD 4.55 billion in 2021 and is expected to reach USD 7.74 Billion By 2030, growing at a CAGR of 6.2% during the forecast period.
What is Parkinson’s Disease Treatment? How Big is Parkinson’s Disease Treatment Market Size?
Parkinson’s disease is a brain condition that causes the loss of nerve cells in a specific area of the brain. It has a wide range of effects on a person, including problems with balance and coordination, blood pressure and thinking, sleep problems, depression, memory difficulties, and stiffness. Though the condition is not curable, there are serval treatment options available such as medicines, surgical treatment, and other therapies.
Levodopa is the main therapy for Parkinson’s. People generally take levodopa along with another medication called carbidopa, which prevents several side effects of levodopa, such as vomiting, low blood pressure, nausea, and restlessness. The Parkinson’s disease treatment market size is growing due to the changing environmental factors and genetic predisposition.
Request Sample Copy of Parkinson’s Disease Treatment Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/global-parkinsons-disease-treatment-market/request-for-sample
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)
Highlights of The Report
Some of the Major Players Are:
To Know Additional Information on Market Players, Download Sample PDF Brochure
Growth Driving Factors
A growing number of the elderly population is the major factor propelling the Parkinson’s disease treatment market demand growth. The development and availability of several supportive therapies, including physiotherapy, surgery, and medications to treat Parkinson’s disease, are estimated to propel the industry’s growth. Rising government investments in research and development coupled with growing healthcare awareness are bolstering the industry demand.
Moreover, the increasing application of L-Dopa and a symptomatic dopamine replacement treatment is accelerating the growth of Parkinson’s disease treatment market sales. Currently, the mGlu4 PAM AP-472 is combined with levodopa to treat Parkinson’s disease. Also, a rise in the number of patient visits to the hospital due to the availability of diagnostic laboratories is expected to uptick the Parkinson’s disease treatment market industry development over the forecast period. Additionally, the surging number of generic drug manufacturers is lifting the industry’s growth.
Directly Purchase a copy of the report with TOC @ https://www.polarismarketresearch.com/checkouts/3171
Recent Developments
Segmental Analysis
Based on drug class, the MAO-inhibitors segment is expected to dominate the market. Monoamine Oxidase Type B (MAO-B) enzyme in the nervous system breaks down Dopamine and other substances found in the brain. It raises the quantity of dopamine available for the brain, which can slightly reduce symptoms of several Parkinson’s Disease (PD) movements. The growing popularity of MOA-B inhibitors is predicted to augment the segment growth in the market.
By route of administration, the oral segment witnessed the largest Parkinson’s disease treatment market share owing to patient compliance, simplicity of consumption, pain avoidance, and adaptability to various drug types. During clinical research, several dopamine agonists are orally administrated, such as ropinirole and pramipexole, thus boosting the demand for oral administration. This factor is likely to extend the market growth.
Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/global-parkinsons-disease-treatment-market/inquire-before-buying
(Inquire a report quote OR available discount offers to the sales team before purchase.)
Parkinson’s Disease Treatment Market: Report Scope
| Report Attribute | Details |
| Market Outlook for 2030 | USD 7.74 Billion |
| Market Size 2022 Value | USD 4.80 Billion |
| Expected CAGR Growth | 6.2% from 2022 – 2030 |
| Base Year | 2021 |
| Forecast Year | 2022 – 2030 |
| Top Market Players | Abbvie Inc., Acadia Pharmaceuticals Inc., Apotex Inc., Axovant Gene Therapies Ltd., Boehringer Ingelheim GmbH, Bausch Health Companies Inc., Boston Scientific Corp., Cipla Inc., Daiichi Sankyo Espha Co., Ltd., Eli Lilly & Co., Eisai Co., Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Impax Laboratories, Inc., Merck & Co. Inc., Mylan Nv, Novartis International AG, Pfizer Inc., Sanofi Sa, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, Llc, And Wockhardt Ltd. |
| Segments Covered | By Drug Class, By Route of Administration, By Patient Care Setting, By Distribution Channel, By Region |
| Customization Options | Customized purchase options are available to meet your research needs. Explore customized purchase options |
Geographic Overview
Depending on geography, Parkinson’s disease treatment market in North America is leading the industry mainly in the U.S. owing to the increasing prevalence of Parkinson’s illness in the country, rising initiatives by government organizations for the treatment of Parkinson’s disorders, and the prevalence of market competitors. PD affects nearly one million Americans. This is expected to reach 1.2 million by 2030.
Moreover, in major European nations, the government is focusing on accelerating research and development of parkinsonism medicines due to the increasing requirement for managing Parkinson’s disease. For instance, according to European Parkinson’s disease Association, more than 1.2 million individuals are suffering from parkinsonism in Europe, and that number is expected to increase by 2030.
Browse the Detail Report “Parkinson’s Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Levodopa/carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics, and Other Drugs); By Distribution Channel; By Route of Administration; By Patient Care Setting; By Region; Segment Forecast, 2022 – 2030” with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/global-parkinsons-disease-treatment-market
For Additional Information OR Media Enquiry, Please Mail Us At: sales@polarismarketresearch.com
Key Questions Answered in The Report
Polaris Market Research has segmented the Parkinson’s Disease Treatment market report based on drug class, distribution channel, route of administration, patient care setting, and region:
By Drug Class Outlook
By Distribution Channel Outlook
By Route of Administration Outlook
By Patient Care Setting Outlook
By Region Outlook
Browse More Related Reports:
Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals.
Parkinson's Disease Treatment Market , Parkinson's Disease Treatment Market Analysis , Parkinson's Disease Treatment Market Growth , Parkinson's Disease Treatment Market Research , Parkinson's Disease Treatment Market Share , Parkinson's Disease Treatment Mark
Jan 23, 2023
Copyright © 2006 - 2023 PRnob Media, UBIC Solutions, LLC. All Rights Reserved.
